DOCSLIB.ORG

WO 2019/090111 Al 09 May 2019 (09.05.2019) W 1P O PCT

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WO 2019/090111 Al 09 May 2019 (09.05.2019) W 1P O PCT (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2019/090111 Al 09 May 2019 (09.05.2019) W 1P O PCT (51) International Patent Classification: (84) Designated States (unless otherwise indicated, for every A61K 31/7064 (2006.01) A61P 33/14 (2006.01) kind of regional protection available): ARIPO (BW, GH, A61K 45/06 (2006.01) A61P 25/28 (2006.01) GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, A61P 35/00 (2006.01) C07F 9/6561 (2006.01) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, A61P 31/12 (2006.01) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, ΓΕ , IS, IT, LT, LU, LV, (21) International Application Number: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, PCT/US20 18/059004 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (22) International Filing Date: KM, ML, MR, NE, SN, TD, TG). 02 November 2018 (02. 11.2018) Declarations under Rule 4.17: (25) Filing Language: English — as to applicant's entitlement to apply for and be granted a (26) Publication Language: English patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the (30) Priority Data: earlier application (Rule 4.17(Hi)) 62/581,574 03 November 2017 (03. 11.2017) US 62/664,841 30 April 2018 (30.04.2018) US Published: — with international search report (Art. 21(3)) (71) Applicant: ORIC PHARMACEUTICALS, INC. — before the expiration of the time limit for amending the [US/US]; 240 E . Grand Avenue, 2nd Floor, South San Fran¬ claims and to be republished in the event of receipt of cisco, California 94080 (US). amendments (Rule 48.2(h)) (72) Inventors: DU, Xiaohui; 240 E . Grand Avenue, 2nd Floor, South San Francisco, California 94080 (US). EKSTEROWICZ, John; 240 E . Grand Avenue, 2nd Floor, South San Francisco, California 94080 (US). FANTIN, Va¬ leria R.; 240 E . Grand Avenue, 2nd Floor, South San Fran¬ cisco, California 94080 (US). JACKSON, Erica L.; 240 E . Grand Avenue, 2nd Floor, South San Francisco, Califor¬ nia 94080 (US). SUN, Daqing; 240 E . Grand Avenue, 2nd Floor, South SanFrancisco, California 94080 (US). YE, Qi- uping; 240 E . Grand Avenue, 2nd Floor, South SanFrancis¬ co, California 94080 (US). MOORE, Jared; 240 E . Grand Avenue, 2nd Floor, South San Francisco, California 94080 (US). ZAVOROTINSKAYA, Tatiana; 240 E . Grand Av¬ enue, 2nd Floor, South San Francisco, California 94080 (US). (74) Agent: SMITH, Deborah M.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. ©O S o (54) Title: CD73 INHIBITORS (57) Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject com¬ pounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases. CD73 INHIBITORS CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Provisional Application Serial Number 62/581,574, filed November 3, 2017, and U.S. Provisional Application Serial Number 62/664,841, filed April 30, 2018 which are all hereby incorporated by reference in their entirety. BACKGROUND [0002] A need exists in t e art for an effective treatment of cancer, infections, and neurodegenerative diseases. BRIEF SUMMARY OF THE INVENTION [0003] Provided herein are compounds of Formulas (I), (II), (Ila), (lib), (III), and (IV) or pharmaceutically acceptable salts, solvates, or stereoisomers thereof, and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as CD73 inhibitors. Furthermore, the subject compounds and compositions are useful for the treatment of cancers, infections, and neurodegenerative diseases. [0004] Provided herein are compounds having the structure of Formula (Ila), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof: Formula (Ila); wherein: A is -O- or -CH2-; Q1 is CW and Q2 is N; or Q1 is N and Q2 is N; a a a a W is hydrogen, halogen, -CN, -OH, -OR , -SH, -SR , -S(=0)R , -N0 2, -NR R , -S(=0) 2R , - a a a b b NHS(=0) 2R , -S(=0) NR R , -C(=0)R , -OC(=0)R , -C(=0)OR , -OC(=0)OR , -C(=0)NR R , -OC(=0)NR R , -NRbC(=0)NR R , -NRbC(=0)R a, -NRbC(=0)OR b, C C alkyl, C -C alkenyl, C2-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-C alkyl(aryl), Ci-C alkyl(heteroaryl), Ci-C alkyl(cycloalkyl), or Ci-C alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R 0; Z is -N^R 2, -OR60, -SR6 1, or -CR R R64; 1 2 R and R are each independently hydrogen, C -C alkyl, C2-C alkenyl, C2-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C -C alkyl(aryl), C -C alkyl(heteroaryl), C -C 1 a a a alkyl(cycloalkyl), C C alkyl(heterocycloalkyl), -S(=0) 2R , -S(=0) 2NR R , or -C(=0) R ; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R ; or R1 and R2 are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R b ; 60 1 1 1 1 R is hydrogen, -C(=0)R , -C(=0)OR , -C(=0)NR R , C C alkyl, C2-C alkenyl, C -C alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-C alkyl(aryl), Ci-C alkyl(heteroaryl), C -C alkyl(cycloalkyl), C -C alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R m; R6 1 is hydrogen, -C(=0)R 1 , -C(=0)OR 1 , -C(=0)NR 1 R1 , C C alkyl, C -C alkenyl, C -C alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C -C alkyl(aryl), C -C alkyl(heteroaryl), C -C alkyl(cycloalkyl), C -C alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R ; R62, R63, and R64 are each independently hydrogen, halogen, -CN, -OH, -OR1 , -SH, -SR1 , - S(=0)R 1 , -N0 , -NR 1 R1 , -S(=0) R1 , -NHS(=0) R1 , -S(=0) NR1 R1 , -C(=0)R 1 , - OC(=0)R 1 , -C(=0)OR 1 , -OC(=0)OR 1 , -C(=0)NR 1 R1 , -OC(=0)NR 1 R1 , - NR1 C(=0)NR 1 R1 , -NR 1 C(=0)R 1 , -NR 1 C(=0)OR 1 , C C alkyl, C -C alkenyl, C -C alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C -C alkyl(aryl), C -C alkyl(heteroaryl), C -C alkyl(cycloalkyl), or C -C alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R °; R3 is halogen, -CN, -OH, -OR1 b , -SR1 b , -NR 1 bR1 , C C alkyl, C -C alkenyl, C -C alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-C alkyl(aryl), Ci-C alkyl(heteroaryl), Ci-C alkyl(cycloalkyl), or C -C alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R ; 4 7 1 1 1 R and R are each independently hydrogen, halogen, -OH, -OR , -NR S(=0) 2R , - 1 1 NR C(=0)R , C -C alkyl, C2-C alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R ; 5 6 1 1 1 R and R are each independently hydrogen, halogen, -OH, -OR , -NR S(=0) 2R , - 1 1 NR C(=0)R , Ci-Ce alkyl, C2-C alkenyl, C2-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R ; X1 is a bond; Y 1 is -S(=0) -; R45 and R4 are each independently hydrogen, halogen, -OH, -ORa, -NR R , C C alkyl, or C C haloalkyl; v2 is 1-3; 1 a 1 b 1 1 1 1 1 R , R , R , R , R , R , R are each independently C C alkyl, C2-C alkenyl, C2-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R ; R1 a, R1 b , R1 , R1 , R1 , R1 , R1 , R1 a, R1 , R1 , R1 , and R1 are each independently hydrogen, C -C alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R ; or R1 a and R1 a or R1 b and R1 or R1 and R1 or R1 and R1 or R1 and R1 are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three halogen, C -C alkyl, or C -C haloalkyl; R1 b is C -C alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C r C alkyl(aryl), C
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Chapter 246-883 WAC PHARMACEUTICAL—SALES REQUIRING PRESCRIPTIONS
    Chapter 246-883 Chapter 246-883 WAC PHARMACEUTICAL—SALES REQUIRING PRESCRIPTIONS WAC Authority: 1979 1st ex. s. c 139. 79-09-138 (Order 149, Resolution No. 246-883-020 Identification of legend drugs for purposes of chapter 9/79), § 360-32-050, filed 9/5/79.] 69.41 RCW. 246-883-025 Introductory trade or stock packages. 246-883-030 Ephedrine prescription restrictions. WAC246-883-025 246-883-025 Introductory trade or stock pack- 246-883-040 Regulated steroids. 246-883-050 Theophylline prescription restrictions. ages. Introductory trade or stock packages may be distributed by registered drug manufacturers to licensed pharmacies 246-883-020 under the following conditions: WAC 246-883-020 Identification of legend drugs for purposes of chapter 69.41 RCW. (1) In accordance with (1) The package shall be invoiced by the drug manufac- chapter 69.41 RCW, the board of pharmacy finds that those turer as a no charge sale. drugs which have been determined by the Food and Drug (2) The product shall be distributed by the manufacturer Administration, under the Federal Food, Drug and Cosmetic to the pharmacy by mail or common carrier. Act, to require a prescription under federal law should also be (3) The drug's package shall not be marked as a sample classified as legend drugs under state law because of their or with any other labeling that is inconsistent with the claim toxicity or potential for harmful effect, the methods of their that the manufacturer intended the package for sale. use and the collateral safeguards necessary to their use, indi- (4) The manufacturer shall be limited to distributing one cate that they are only safe for use under the supervision of a introductory package of each dosage strength of a product on practitioner.
    [Show full text]
  • Buy Trestolone Australia
    Buy Trestolone Australia → CLICK TO VISIT OUR ONLINE SHOP ← Buy Trestolone Decanoate dissolved in a sterile solution of grape seed oil. Contains 1000mg of sample chemical - 100mg/mL Best pric Free Ship $150.00+ #biayr #brain #braininjury #braininjuryawareness #braininjuryrecovery #braininjurysupport #braininjurysurvivor #braininjurysurvivors #abi #tbi #tbiawareness #tbisurvivor #braininjuryassociation #yorkregion #richmondhill #vaughan #aurora #newmarket #markham #whitchurchstouffville #eastgwillimbury #georgina #unionville #kleinburg #kingcity #nutrition #healthyeating I’ve been scouring Pinterest lately for recipes involving fresh figs. I’ve found some that I can’t wait to try, like roasted figs stuffed with goat cheese, bacon and fig flatbread, and (sure to be my favorite!) homemade fig newtons! http://alphabolin-uk-muscle.over-blog.com/2020/10/primobolan-cena-apteka-alphabolin-100-mg-1-vial-10-ml.html https://www.pinterest.com/pin/652318327270651239/ i wanna buy Trestolone acetate liquid 10 ml. ... Do u ship to Thailand and if u do how long it takes to get to me I will like to order 2 bottles of trestolone. Rated 5 out of 5. Rameen Hashemiyoon (verified owner) ... #polilla somos parte de algo más grande que nosotros. #nature #home #house #naturephotography #naturelover #beastmode #gym #gymgoals #gymshark #muscle #fitnesschef #gymfood #mexico #queretaro #instadaily #progress #instagram #instafit #instagay #ripped #gymmotivation #fitfam #fitnessmotivation #gymlife #bulking #gymtime #picoftheday Sumo and 3ct bench #IrishPF #irishpowerliftingfederation #nipf #roguefitness #squats #a7uk #sbd #reform #customstrength #deadlift #bench #powerlifting #strength #strengthtraining #repower #9for9 #eleiko #wahlander #onlinecoaching #inzer @reform_health_performance MENT is extremely potent and hard to find, scoring 2300/650 on the anabolic androgenic ratio so be careful of cheap imitations of IA Superpharma trestolone acetate.
    [Show full text]
  • (12) United States Patent (Lo) Patent No.: US 8,480,637 B2
    111111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (lo) Patent No.: US 8,480,637 B2 Ferrari et al. (45) Date of Patent : Jul. 9, 2013 (54) NANOCHANNELED DEVICE AND RELATED USPC .................. 604/264; 907/700, 902, 904, 906 METHODS See application file for complete search history. (75) Inventors: Mauro Ferrari, Houston, TX (US); (56) References Cited Xuewu Liu, Sugar Land, TX (US); Alessandro Grattoni, Houston, TX U.S. PATENT DOCUMENTS (US); Daniel Fine, Austin, TX (US); 5,651,900 A 7/1997 Keller et al . .................... 216/56 Randy Goodall, Austin, TX (US); 5,728,396 A 3/1998 Peery et al . ................... 424/422 Sharath Hosali, Austin, TX (US); Ryan 5,770,076 A 6/1998 Chu et al ....................... 210/490 5,798,042 A 8/1998 Chu et al ....................... 210/490 Medema, Pflugerville, TX (US); Lee 5,893,974 A 4/1999 Keller et al . .................. 510/483 Hudson, Elgin, TX (US) 5,938,923 A 8/1999 Tu et al . ........................ 210/490 5,948,255 A * 9/1999 Keller et al . ............. 210/321.84 (73) Assignees: The Board of Regents of the University 5,985,164 A 11/1999 Chu et al ......................... 516/41 of Texas System, Austin, TX (US); The 5,985,328 A 11/1999 Chu et al ....................... 424/489 Ohio State University Research (Continued) Foundation, Columbus, OH (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/036623 4/2004 WO WO 2006/113860 10/2006 patent is extended or adjusted under 35 WO WO 2009/149362 12/2009 U.S.C. 154(b) by 612 days.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua Et Al
    US 2002001 0208A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua et al. (43) Pub. Date: Jan. 24, 2002 (54) DHA-PHARMACEUTICAL AGENT Related U.S. Application Data CONJUGATES OF TAXANES (63) Continuation of application No. 09/135,291, filed on (76) Inventors: Victor Shashoua, Brookline, MA (US); Aug. 17, 1998, now abandoned, which is a continu Charles Swindell, Merion, PA (US); ation of application No. 08/651,312, filed on May 22, Nigel Webb, Bryn Mawr, PA (US); 1996, now Pat. No. 5,795,909. Matthews Bradley, Layton, PA (US) Publication Classification Correspondence Address: Edward R. Gates, Esq. (51) Int. Cl." ............................................ A61K 31/337 Wolf, Greenfield & Sacks, P.C. (52) U.S. Cl. .............................................................. 514/449 600 Atlantic Avenue Boston, MA 02210 (US) (57) ABSTRACT The invention provides conjugates of cis-docosahexaenoic (21) Appl. No.: 09/846,838 acid and pharmaceutical agents useful in treating noncentral nervous System conditions. Methods for Selectively target 22) Filled: Mayy 1, 2001 ingg pharmaceuticalp agents9. to desired tissues are pprovided. Patent Application Publication Jan. 24, 2002 Sheet 1 of 14 US 2002/0010208A1 1 OO 5 O -5OO - 1 OO-9 -8 -7 -6 -5 -4 LOG-10 OF SAMPLE CONCENTRATION (MOLAR) CCRF-CEM-o- SR ----- RPM-8226----- K-562- - -A - - HL-60 (TB) -g- - MOLT4: ... O Fig. 1 1 OO 5 O -5OO -1 O O -8 -7 -6 -5 -4 -- 9 LOGo OF SAMPLE CONCENTRATION (MOLAR) A549/ATCC-o-NS326. NCEKVX 28. --Q-- NCI-H322M-...-a---Eidsf8::... NC-H522--O-- HOP-62---Fig. 2 a-- NC-H460.-------- Patent Application Publication Jan.
    [Show full text]
  • WO 2016/210165 Al 29 December 2016 (29.12.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/210165 Al 29 December 2016 (29.12.2016) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 471/04 (2006.01) A61K 31/4985 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 487/04 (2006.01) A61P 35/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/519 (2006.01) A61P 17/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/437 (2006.01) A61P 19/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US20 16/039070 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 23 June 2016 (23.06.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/183,969 24 June 2015 (24.06.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/271,715 28 December 201 5 (28.
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]
  • (12) United States Patent (Io) Patent No.: US 9,526,824 B2 Ferrari Et Al
    1111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (io) Patent No.: US 9,526,824 B2 Ferrari et al. (45) Date of Patent: Dec. 27, 2016 (54) NANOCHANNELED DEVICE AND RELATED (52) U.S. Cl. METHODS CPC .............. A61M 5/00 (2013.01); A61K 9/0097 (2013.01); A61M37/00 (2013.01); (71) Applicants:The Board of Regents of the (Continued) University of Texas System, Austin, TX (US); The Ohio State University (58) Field of Classification Search Research Foundation, Columbus, OH CPC ............. B81C 1/00444; B81C 1/00476; B81C (US) 1/00119; BO1D 67/0034; YIOS 148/05 (Continued) (72) Inventors: Mauro Ferrari, Houston, TX (US); Xuewu Liu, Sugar Land, TX (US); (56) References Cited Alessandro Grattoni, Houston, TX (US); Daniel Fine, Austin, TX (US); U.S. PATENT DOCUMENTS Randy Goodall, Austin, TX (US); Sharath Hosali, Austin, TX (US); 3,731,681 A 5/1973 Blackshear et al. Ryan Medema, Pflugerville, TX (US); 3,921,636 A 11/1975 Zaffaroni Lee Hudson, Elgin, TX (US) (Continued) (73) Assignees: The Board of Regents of the FOREIGN PATENT DOCUMENTS University of Texas System, Austin, TX (US); The Ohio State University CN 1585627 2/2005 Research Foundation, Columbus, OH DE 10 2006 014476 7/2007 (US) (Continued) (*) Notice: Subject to any disclaimer, the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U.S.C. 154(b) by 784 days. "The Economic Costs of Drug Abuse in the United States," www. whitehousedrugpolicy.gov, Sep. 2001. (21) Appl. No.: 13/875,871 (Continued) (22) Filed: May 2, 2013 Primary Examiner Binh X Tran (65) Prior Publication Data (74) Attorney, Agent, or Firm Parker Highlander PLLC US 2013/0240483 Al Sep.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0361298 A1 Novick Et Al
    US 20160361298A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0361298 A1 Novick et al. (43) Pub. Date: Dec. 15, 2016 (54) METHODS AND COMPOSITIONS FOR A63/496 (2006.01) TREATING CANCER A 6LX 39/395 (2006.01) (71) Applicant: Globavir BioSciences, Inc., Los Altos, A63/496 (2006.01) CA (US) A63L/452 (2006.01) A6II 45/06 (2006.01) (72) Inventors: Paul Novick, San Francisco, CA (US); C07K 6/28 (2006.01) Jonathan Choy, Lafayette, CA (US); A6II 3/478 (2006.01) Sumit Mahajan, Foster City, CA (US); Ritika Prasad, Mountain View, CA A6II 3/167 (2006.01) (US); Shalabh Gupta, Mountain View, (52) U.S. Cl. CA (US) CPC ....... A61K 31/4174 (2013.01); A61K 31/41 78 (2013.01); A61K 31/4184 (2013.01); A61 K (21) Appl. No.: 15/179,764 3 1/496 (2013.01); A61K 31/167 (2013.01); (22) Filed: Jun. 10, 2016 A61K 31/4196 (2013.01); A61K 31/4152 (2013.01); A61K 45/06 (2013.01); C07K Related U.S. Application Data 16/2818 (2013.01); A61K 39/3955 (2013.01); (60) Provisional application No. 62/174,430, filed on Jun. A6 IK 2039/505 (2013.01) 11, 2015, provisional application No. 62/174,424, filed on Jun. 11, 2015, provisional application No. (57) ABSTRACT 62/188.413, filed on Jul. 2, 2015, provisional appli cation No. 62/195,750, filed on Jul. 22, 2015. Described are compositions and methods for treating cancer. Some methods comprise the administration of an effective Publication Classification amount of at least one inhibitor of tryptophan 2,3-dioxy (51) Int.
    [Show full text]
  • Truesdail Laboratories, Inc
    I ORIG INAL I TRUESDAIL LABORATORIES, INC. Response to The Nebraska State Racing Commission The Nebraska State Racing Commission Request for Solicitation Number RFP 5702 Zl for Equine Drug Testing Laboratory Services 2018-2021 Due November 2, 2017 at 2:00 PM CDT Section 1 - Cover Letter Section 2 - Table of Contents TRUESDAIL LABORATORIES Section 3 - Form A (Bidder Contact Sheet) Proposal to Nebraska State Racing Section 4 -Bidder Signature Page Commission For: Section 5 - Completed Sections II Equine Drug Testing Through IV Laboratory Services 2018-2021 Section 6 - Completed Section R (Bidder Requirements) Due: November 2, 2017 at 2:00 PM COT Section 7 - Corporate Overview Section 8 - Technical Approach Section 9 - Cost Proposal Requirements ) Appendices I• TRUESDAIL LABORATORIES, INC. Proposal to: Nebraska State Racing Commission Request for Proposal - Analysis of Equine Urine and Blood Samples RFP 5702 Z1 - November 2017 Section 1 - Cover Letter November 1st, 2017 Ms. Teresa Fleming I Ms. Michelle Thompson State Procurement Office STATE OF NEBRASKA 1526 K Street, Suite 130 Lincoln, Nebraska 68508 Re: RFP 5702 Z1 - Nebraska State Racing Co_mmission - Analysis of Equine Urine and Blood Drug Testing Laboratory Services Dear Ms. Fleming and/or Ms. Thompson: Truesdail Laboratories, Inc (Truesdail} is pleased to submit this bid in response to the Request for Proposal 5702 Z1 (RFP). Truesdail has serviced the Nebraska State Racing Commission (Commission) with equine drug testing since 2009 and we hope to continue that relationship. There is no laboratory in the U.S. that has as many years of experience in equine drug testing as Truesdail. Truesdail has experience with applying every typical instrumental screening and confirmation test as required by the RFP.
    [Show full text]
  • Aasraw Biochemical Technology Co., Ltd
    AASraw Biochemical Technology Co., Ltd. www.aasraw.com [email protected] Whatsapp: +8618928439036 Skype: live:7033c4943e7489ec Product Series Product Name CAS Boldenone Series 1 Boldenone 846-48-0 2 Boldenone Acetate 2363-59-9 3 Boldenone Cypionate 106505-90-2 4 Boldenone Undecylenate/EQ 13103-34-9 Trenbolone Series 1 Trenbolone 10161-33-8 2 Trenbolone Acetate 10161-34-9 3 Trenbolone Enanthate 10161-35-8 4 Trenbolone Hexahydrobenzyl Carbonate23454-33-3 5 Methyltrienolone 965-93-5 Nandrolon Series 1 Nandrolone 434-22-0 2 Nandrolone Decanoate/DECA 360-70-3 3 Nandrolone phenylpropionate/NPP 62-90-8 4 Nandrolone cypionate 601-63-8 5 Nandrolone laurate 26490-31-3 6 Nandrolone propionate 7207-92-3 7 Nandrolone undecylate 862-89-5 8 Stanolone 521-18-6 Testosterone Series Anabolics 1 Testosterone 58-22-0 Steroids 2 Testosterone acetate 1045-69-8 3 Testosterone cypionate 58-20-8 4 Testosterone decanoate 5721-91-5 5 Testosterone enanthate 315-37-7 6 Testosterone phenylpropionate 1255-49-8 7 Testosterone isocaproate 15262-86-9 8 Testosterone propionate 57-85-2 9 Testosterone Sustanon 250 10 Testosterone undecanoate 5949-44-0 11 Methyltestosterone 58-18-4 Anabolics Steroids Clostebol Acetate/4- Chlorotestosterone 12 acetate/Turinabol/Tbol 855-19-6 13 Oral turinabol 2446-23-3 Methenolone Series 1 Methenolone Acetate 434-05-9 Drostanolone2 Methenolone Enanthate 303-42-4 Series 1 Drostanolone/Masteron Enanthate 472-61-1 2 Drostanolone/Masteron Propionate 521-12-0 3 Methasteron/Superdrol 3381-88-2 Oral steroids 1 Oxandrolone/Anavar 53-39-4 2 Oxymetholone/Anadrol
    [Show full text]